2027 NCODA Global Oncology & Haematology Congress
March 10, 2027 | 9:00 AM EST
A Retrospective Analysis: Montelukast Prophylaxis to Support Patient-Centered Oncology Care
Published Date:
Share
Siân Behrendt-McLeroy, PharmD, MS, is a Clinical Oncology Pharmacist, and Brandon Dyson, PharmD, BCOP, BCPS, is Director of Pharmacy Education at Texas Oncology in Austin, Texas. Jacob Enis, PharmD, is Pharmacy Manager at Texas Oncology South Austin in Austin, Texas. Urooj Iqbal, PharmD, BCOP, is Pharmacy Review Team Supervisor at Texas Oncology in Dallas, Texas.
1. RITUXAN® [rituximab] prescribing information. South San Francisco, CA: Genentech; 2021. [Internet. Accessed January 26, 2026.] Available from: https://www.gene.com/download/pdf/ rituxan_prescribing.pdf.
2. Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol. 2019;15(4):383- 389. doi:10.1080/1744666X.2019.1562905.
3. Salles G, Barrett M, Foà R, et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther. 2017;34(10):2232- 2273. doi:10.1007/s12325-017-0612-x.
4. Amatto L, Yacyshyn E. Montelukast as a Rescue and Premedication for Rituximab Infusion Reactions. J Rheumatol. 2024;51(8):837. Published 2024 Aug 1. doi:10.3899/ jrheum.2024-0116.
5. Crespo A, Forbes L, Gallo-Hershberg D, et al. Management of cancer medication related infusion reactions. Cancer Care Ontario; 2019. [Internet. Accessed March 2, 2026.] Available from: https:// www.cancercareontario.ca/sites/ ccocancercare/files/guidelines/full/ ManagementCancerMedicationRelatedInfusionReactions.pdf.
6. Kotchetkov R, McLean J, Gerard L, Nay D, Hopkins SP. Effect of montelukast and rupatadine on rituximab infusion time, rate, severity of reactions, and cost of administration. J Clin Oncol. 2019; 37: 6500-6500. doi: 10.1200/ JCO.2019.37.15_suppl.6500.
7. Kotchetkov R, McLean J, Nay D, Gerard L, Hopkins S, Didiodato G. Premedication with montelukast and rupatadine decreased rituximab infusion time, rate, severity of reactions and use of rescue medications. Int J Cancer. 2020;147(7):1979-1986. doi:10.1002/ijc.32985.
8. Chari A, Lonial S, Mark TM, et al. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma. Cancer. 2018;124(22):4342-4349. doi:10.1002/cncr.31706
9. Breslow R, Caiado J, Castells M. Acetylsalicylic acid and montelukast block mast cell mediator– related symptoms during rapid desensitization. Ann Allergy Asthma Immunol. 2009; 102:155-60.
10. SINGULAIR (montelukast sodium) tablets, chewable tablets, oral granules. Prescribing information. Merck Sharp & Dohme Corp; 2020. [Internet. Accessed September 18, 2026.] https://www.fda.gov/drugsatfda
11. US Food and Drug Administration. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. FDA Drug Safety Communication. March 4, 2020. [Internet. Accessed September 18, 2026.] https://www.fda.gov/drugs/ drug-safety-communications/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug
12. Mahmood O, Leung C, Tohan P et al. Evaluating the efficacy of montelukast in reducing the incidence and severity of monoclonal antibodies-associated infusion reactions (Phase II Study). Blood 2025; 146 (Supplement 1): 6196. doi: https://doi.org/10.1182/blood-2025-6196.
13. Numiqo Team (2026). numiqo: Online Statistics Calculator. numiqo e.U. Graz, Austria. [Accessed March 6, 2026] URL https://numiqo.com.
Send your feedback
Please do not include any personal information or details.
"*" indicates required fields
Was this page
helpful?
Send your feedback
Please do not include any personal information or details.
"*" indicates required fields